A heterogeneous group of bone dysplasias, the common character of which is stippling of the epiphyses in infancy. The group includes a severe autosomal recessive form (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC), an autosomal dominant form (Conradi-Hunermann syndrome), and a milder X-linked form. Metabolic defects associated with impaired peroxisomes are present only in the rhizomelic form.
An autosomal recessive form of CHONDRODYSPLASIA PUNCTATA characterized by defective plasmalogen biosynthesis and impaired peroxisomes. Patients have shortened proximal limbs and severely disturbed endochondral bone formation. The metabolic defects associated with the impaired peroxisomes are present only in the rhizomelic form of chondrodysplasia punctata. (From Scriver et al, Metabolic Basis of Inherited Disease, 6th ed, p1497)
GLYCEROPHOSPHOLIPIDS in which one of the two acyl chains is attached to glycerol with an ether alkenyl linkage instead of an ester as with the other glycerophospholipids.
A 20-carbon branched chain fatty acid. In phytanic acid storage disease (REFSUM DISEASE) this lipid may comprise as much as 30% of the total fatty acids of the plasma. This is due to a phytanic acid alpha-hydroxylase deficiency.
A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.
An autosomal recessive familial disorder that usually presents in childhood with POLYNEUROPATHY; SENSORINEURAL HEARING LOSS; ICHTHYOSIS; ATAXIA; RETINITIS PIGMENTOSA; and CARDIOMYOPATHIES. (From Joynt, Clinical Neurology, 1991, Ch37, p58-9; Rev Med Interne 1996;17(5):391-8) This condition can be caused by mutation in the genes encoding peroxisomal phytanoyl-CoA hydroxylase or proteins associated peroxisomal membrane, leading to impaired catabolism of PHYTANIC ACID in PEROXISOMES.
An autosomal recessive disorder due to defects in PEROXISOME biogenesis which involves more than 13 genes encoding peroxin proteins of the peroxisomal membrane and matrix. Zellweger syndrome is typically seen in the neonatal period with features such as dysmorphic skull; MUSCLE HYPOTONIA; SENSORINEURAL HEARING LOSS; visual compromise; SEIZURES; progressive degeneration of the KIDNEYS and the LIVER. Zellweger-like syndrome refers to phenotypes resembling the neonatal Zellweger syndrome but seen in children or adults with apparently intact peroxisome biogenesis.
Abnormal development of cartilage and bone.
An enzyme that catalyzes the formation of acetoacetyl-CoA from two molecules of ACETYL COA. Some enzymes called thiolase or thiolase-I have referred to this activity or to the activity of ACETYL-COA C-ACYLTRANSFERASE.
Enzymes that catalyze the hydrolysis of a phenol sulfate to yield a phenol and sulfate. Arylsulfatase A, B, and C have been separated. A deficiency of arylsulfatases is one of the causes of metachromatic leukodystrophy (LEUKODYSTROPHY, METACHROMATIC). EC 3.1.6.1.
Electron-dense cytoplasmic particles bounded by a single membrane, such as PEROXISOMES; GLYOXYSOMES; and glycosomes.
Enzymes from the transferase class that catalyze the transfer of acyl groups from donor to acceptor, forming either esters or amides. (From Enzyme Nomenclature 1992) EC 2.3.
Microbodies which occur in animal and plant cells and in certain fungi and protozoa. They contain peroxidase, catalase, and allied enzymes. (From Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 2nd ed)
Hereditary disorder transmitted by an autosomal dominant gene and characterized by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Developmental bone diseases are a category of skeletal disorders that arise from disturbances in the normal growth and development of bones, including abnormalities in size, shape, structure, or composition, which can lead to various musculoskeletal impairments and deformities.
Insects of the order Dictyoptera comprising several families including Blaberidae, BLATTELLIDAE, Blattidae (containing the American cockroach PERIPLANETA americana), Cryptocercidae, and Polyphagidae.

Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. (1/23)

Rhizomelic chondrodysplasia punctata is an autosomal recessive disorder characterized by stippled epiphyses and rhizomelic shortening of the long bones. Most fetuses with the disorder die in utero or shortly thereafter, and the few that survive suffer severe debility and profound mental retardation. Death ensues in the first decade of life. Relatively few reports discuss antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. We describe the prospective antenatal diagnosis of rhizomelic chondrodysplasia punctata in a fetus with no family history of the disorder, based on the sonographic findings of severe rhizomelic limb shortening in combination with premature ossification and stippling of multiple epiphyses. The ultrasonographic features and differential diagnosis of rhizomelic chondrodysplasia punctata are elaborated.  (+info)

Ether lipid biosynthesis: alkyl-dihydroxyacetonephosphate synthase protein deficiency leads to reduced dihydroxyacetonephosphate acyltransferase activities. (2/23)

Recent studies have indicated that two peroxisomal enzymes involved in ether lipid synthesis, i.e., dihydroxyacetonephosphate acyltransferase and alkyl-dihydroxyacetonephosphate synthase, are directed to peroxisomes by different targeting signals, i.e., peroxisomal targeting signal type 1 and type 2, respectively. In this study, we describe a new human fibroblast cell line in which alkyl-dihydroxyacetonephosphate synthase was found to be deficient both at the level of enzyme activity and enzyme protein. At the cDNA level, a 128 base pair deletion was found leading to a premature stop. Remarkably, dihydroxyacetonephosphate acyltransferase activity was strongly reduced to a level comparable to the activities measured in fibroblasts from patients affected by the classical form of rhizomelic chondrodysplasia punctata (caused by a defect in peroxisomal targeting signal type 2 import). Dihydroxyacetonephosphate acyltransferase activity was completely normal in another alkyl-dihydroxyacetonephosphate synthase activity-deficient patient. Fibroblasts from this patient showed normal levels of the synthase protein and inactivity results from a point mutation leading to an amino acid substitution. These results strongly suggest that the activity of dihydroxyacetonephosphate acyltransferase is dependent on the presence of alkyl-dihydroxyacetonephosphate synthase protein. This interpretation implies that the deficiency of dihydroxyacetonephosphate acyltransferase (targeted by a peroxisomal targeting signal type 1) in the classic form of rhizomelic chondrodysplasia punctata is a consequence of the absence of the alkyl-dihydroxyacetonephosphate synthase protein (targeted by a peroxisomal targeting signal type 2).  (+info)

MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata. (3/23)

A case of rhizomelic chondrodysplasia punctata was investigated with MR imaging of the brain and hydrogen-1 MR spectroscopy of the brain and blood. Areas with abnormal signal hyperintensity on T2-weighted images or hypointensity on T1-weighted images were detected in the subcortical white matter. MR spectroscopy of the brain showed that normal-appearing white matter was characterized by increased levels of mobile lipids and myo-inositol, reduced levels of choline, and the presence of acetate. The importance of these metabolic anomalies is correlated to the deficiency in plasmalogen biosynthesis.  (+info)

Functional studies on human Pex7p: subcellular localization and interaction with proteins containing a peroxisome-targeting signal type 2 and other peroxins. (4/23)

Pex7p is a WD40-containing protein involved in peroxisomal import of proteins containing an N-terminal peroxisome-targeting signal (PTS2). The interaction of human recombinant Pex7p expressed in different hosts/systems with its PTS2 ligand and other peroxins was analysed using various experimental approaches. Specific binding of human Pex7p to PTS2 could be demonstrated only when Pex7p was formed in vitro by a coupled transcription/translation system or synthesized in vivo in Chinese hamster ovary K1 cells transfected with a construct coding for a Pex7p-green fluorescent protein (GFP) fusion protein. Apparently, no cofactors are required and only monomeric Pex7p binds to PTS2. The interaction is reduced upon cysteine alkylation and is impaired upon truncation of the N-terminus of Pex7p. Interaction of Pex7p with other peroxins could not be demonstrated in bacterial or yeast two-hybrid screens, or in pull-down binding assays. The GFP fusion proteins, tagged at either the N- or C-terminus, were able to restore PTS2 import in rhizomelic chondrodysplasia punctata fibroblasts, and Pex7p-GFP was located both in the lumen of peroxisomes and in the cytosol.  (+info)

Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. (5/23)

Although known for almost 80 years, the physiological role of plasmalogens (PLs), the major mammalian ether lipids (ELs), is still enigmatic. Humans that lack ELs suffer from rhizomelic chondrodysplasia punctata (RCDP), a peroxisomal disorder usually resulting in death in early childhood. In order to learn more about the functions of ELs, we generated a mouse model for RCDP by a targeted disruption of the dihydroxyacetonephosphate acyltransferase gene. The mutant mice revealed multiple abnormalities, such as male infertility, defects in eye development, cataract and optic nerve hypoplasia, some of which were also observed in RCDP. Mass spectroscopic analysis demonstrated the presence of highly unsaturated fatty acids including docosahexaenoic acid (DHA) in brain PLs and the occurrence of PLs in lipid raft microdomains (LRMs) isolated from brain myelin. In mutants, PLs were completely absent and the concentration of brain DHA was reduced. The marker proteins flotillin-1 and F3/contactin were found in brain LRMs in reduced concentrations. In addition, the gap junctional protein connexin 43, known to be recruited to LRMs and essential for lens development and spermatogenesis, was down-regulated in embryonic fibroblasts of the EL-deficient mice. Free cholesterol, an important constituent of LRMs, was found in these fibroblasts to be accumulated in a perinuclear compartment. These data suggest that the EL-deficient mice allow the identification of new phenotypes not related so far to EL-deficiency (male sterility, defects in myelination and optic nerve hypoplasia) and indicate that PLs are required for the correct assembly and function of LRMs.  (+info)

Impaired neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata. (6/23)

Rhizomelic chondrodysplasia punctata is a human autosomal recessive disorder characterized by skeletal, eye and brain abnormalities. The disorder is caused by mutations in the PEX7 gene, which encodes the receptor for a class of peroxisomal matrix enzymes. We describe the generation and characterization of a Pex7 mouse knockout (Pex7(-/-)). Pex7(-/-) mice are born severely hypotonic and have a growth impairment. Mortality in Pex7(-/-) mice is highest in the perinatal period although some Pex7(-/-) mice survived beyond 18 months. Biochemically Pex7(-/-) mice display the abnormalities related to a Pex7 deficiency, i.e. a severe depletion of plasmalogens, impaired alpha-oxidation of phytanic acid and impaired beta-oxidation of very-long-chain fatty acids. In the intermediate zone of the developing cerebral cortex Pex7(-/-) mice have an increase in neuronal density. In vivo neuronal birthdating revealed that Pex7(-/-) mice have a delay in neuronal migration. Analysis of bone ossification in newborn Pex7(-/-) mice revealed a defect in ossification of distal bone elements of the limbs as well as parts of the skull and vertebrae. These findings demonstrate that Pex7 knockout mice provide an important model to study the role of peroxisomal functioning in the pathogenesis of the human disorder.  (+info)

The import receptor Pex7p and the PTS2 targeting sequence. (7/23)

This chapter concerns one branch of the peroxisome import pathway for newly-synthesized peroxisomal proteins, specifically the branch for matrix proteins that contain a peroxisome targeting sequence type 2 (PTS2). The structure and utilization of the PTS2 are discussed, as well as the properties of the receptor, Pex7p, which recognizes the PTS2 sequence and conveys these proteins to the common translocation machinery in the peroxisome membrane. We also describe the recent evidence that this receptor recycles into the peroxisome matrix and back out to the cytosol in the course of its function. Pex7p is assisted in its functioning by several species-specific auxiliary proteins that are described in the following chapter.  (+info)

Peroxisome biogenesis disorders. (8/23)

Defects in PEX genes impair peroxisome assembly and multiple metabolic pathways confined to this organelle, thus providing the biochemical and molecular bases of the peroxisome biogenesis disorders (PBD). PBD are divided into two types--Zellweger syndrome spectrum (ZSS) and rhizomelic chondrodysplasia punctata (RCDP). Biochemical studies performed in blood and urine are used to screen for the PBD. DNA testing is possible for all of the disorders, but is more challenging for the ZSS since 12 PEX genes are known to be associated with this spectrum of PBD. In contrast, PBD-RCDP is associated with defects in the PEX7 gene alone. Studies of the cellular and molecular defects in PBD patients have contributed significantly to our understanding of the role of each PEX gene in peroxisome assembly.  (+info)

Chondrodysplasia punctata is a group of genetic disorders that affect the development of bones and cartilage. The condition is characterized by stippled calcifications, or spots of calcium deposits, in the cartilage that can be seen on X-rays. These spots are typically found at the ends of long bones, in the sternum, and in the pelvis.

The symptoms of chondrodysplasia punctata can vary widely depending on the specific type of the disorder. Some people with the condition may have short stature, bowed legs, and other skeletal abnormalities, while others may have only mild symptoms or no symptoms at all. The condition can also be associated with developmental delays, intellectual disability, and other health problems.

There are several different types of chondrodysplasia punctata, each caused by a different genetic mutation. Some forms of the disorder are inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) in order to develop the condition. Other forms of chondrodysplasia punctata are inherited in an X-linked dominant manner, meaning that a single copy of the mutated gene (on the X chromosome) is enough to cause the disorder in females. Males, who have only one X chromosome, will typically be more severely affected by X-linked dominant disorders.

There is no cure for chondrodysplasia punctata, and treatment is focused on managing the symptoms of the condition. This may include physical therapy, bracing or surgery to correct skeletal abnormalities, and medications to manage pain or other health problems.

Chondrodysplasia punctata, rhizomelic is a rare genetic disorder that affects the development of bones and cartilage. The condition is characterized by shortened limbs (rhizomelia), particularly the upper arms and thighs, and multiple small punctate calcifications in the cartilage of the body, including the ears, nose, and other areas.

The disorder is caused by mutations in the gene PEX7, which is involved in the transport of enzymes to peroxisomes, cellular organelles that break down fatty acids and other substances. Without functional PEX7, these enzymes cannot reach the peroxisomes, leading to abnormal accumulation of lipids and other substances in various tissues, including bone and cartilage.

Chondrodysplasia punctata, rhizomelic is typically diagnosed in infancy or early childhood based on clinical features and imaging studies. The condition can be associated with a range of complications, including developmental delays, respiratory problems, hearing loss, and visual impairment. There is no cure for the disorder, and treatment is focused on managing symptoms and addressing specific complications as they arise.

Plasmalogens are a type of complex lipid called glycerophospholipids, which are essential components of cell membranes. They are characterized by having a unique chemical structure that includes a vinyl ether bond at the sn-1 position of the glycerol backbone and an ester bond at the sn-2 position, with the majority of them containing polyunsaturated fatty acids. The headgroup attached to the sn-3 position is typically choline or ethanolamine.

Plasmalogens are abundant in certain tissues, such as the brain, heart, and skeletal muscle. They have been suggested to play important roles in cellular functions, including membrane fluidity, signal transduction, and protection against oxidative stress. Reduced levels of plasmalogens have been associated with various diseases, including neurological disorders, cardiovascular diseases, and aging-related conditions.

Phytanic acid is a branched-chain fatty acid that is primarily found in animal products, such as dairy foods and meat, but can also be present in some plants. It is a secondary plant metabolite that originates from the breakdown of phytol, a component of chlorophyll.

Phytanic acid is unique because it contains a methyl group branching off from the middle of the carbon chain, making it difficult for the body to break down and metabolize. Instead, it must be degraded through a process called α-oxidation, which takes place in peroxisomes.

In some cases, impaired phytanic acid metabolism can lead to a rare genetic disorder known as Refsum disease, which is characterized by the accumulation of phytanic acid in various tissues and organs, leading to neurological symptoms, retinal degeneration, and cardiac dysfunction.

Peroxisomal disorders are a group of inherited metabolic diseases caused by defects in the function or structure of peroxisomes, which are specialized subcellular organelles found in the cells of animals, plants, and humans. These disorders can affect various aspects of metabolism, including fatty acid oxidation, bile acid synthesis, and plasma cholesterol levels.

Peroxisomal disorders can be classified into two main categories: single peroxisomal enzyme deficiencies and peroxisome biogenesis disorders (PBDs). Single peroxisomal enzyme deficiencies are characterized by a defect in a specific enzyme found within the peroxisome, while PBDs are caused by problems with the formation or assembly of the peroxisome itself.

Examples of single peroxisomal enzyme deficiencies include X-linked adrenoleukodystrophy (X-ALD), Refsum disease, and acyl-CoA oxidase deficiency. PBDs include Zellweger spectrum disorders, such as Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease.

Symptoms of peroxisomal disorders can vary widely depending on the specific disorder and the severity of the enzyme or biogenesis defect. They may include neurological problems, vision and hearing loss, developmental delays, liver dysfunction, and skeletal abnormalities. Treatment typically focuses on managing symptoms and addressing any underlying metabolic imbalances.

Refsum Disease is a rare inherited neurological disorder characterized by the accumulation of phytanic acid in various tissues of the body due to impaired breakdown of this fatty acid. This is caused by a deficiency in the enzyme phytanoyl-CoA hydroxylase or the transporter protein peroxisomal biogenesis factor 7 (PEX7).

The symptoms of Refsum Disease can vary but often include progressive neurological dysfunction, retinitis pigmentosa leading to decreased vision and night blindness, hearing loss, ichthyosis (dry, scaly skin), and cardiac abnormalities. The onset of symptoms is usually in childhood or adolescence, but milder cases may not become apparent until later in life.

The treatment for Refsum Disease involves a strict diet that limits the intake of phytanic acid, which is found in dairy products, beef, and certain fish. Plasmapheresis, a procedure to remove harmful substances from the blood, may also be used to reduce the levels of phytanic acid in the body. Early diagnosis and treatment can help slow down or prevent the progression of the disease.

Zellweger Syndrome is a rare genetic disorder that affects the development and function of multiple organ systems in the body. It is part of a group of conditions known as peroxisome biogenesis disorders (PBDs), which are characterized by abnormalities in the structure and function of peroxisomes, which are cellular structures that break down fatty acids and other substances in the body.

Zellweger Syndrome is caused by mutations in one or more genes involved in the formation and maintenance of peroxisomes. As a result, people with this condition have reduced levels of certain enzymes that are necessary for normal brain development, as well as for the breakdown of fats and other substances in the body.

Symptoms of Zellweger Syndrome typically appear within the first few months of life and may include:

* Severe developmental delays and intellectual disability
* Hypotonia (low muscle tone) and poor motor skills
* Vision and hearing problems
* Facial abnormalities, such as a high forehead, wide-set eyes, and a prominent nasal bridge
* Liver dysfunction and jaundice
* Seizures
* Feeding difficulties and failure to thrive

There is no cure for Zellweger Syndrome, and treatment is focused on managing the symptoms of the condition. The prognosis for people with this disorder is generally poor, with most individuals not surviving beyond the first year of life. However, some individuals with milder forms of the condition may live into early childhood or adolescence.

Osteochondrodysplasias are a group of genetic disorders that affect the development of bones and cartilage. These conditions can result in dwarfism or short stature, as well as other skeletal abnormalities. Osteochondrodysplasias can be caused by mutations in genes that regulate bone and cartilage growth, and they are often characterized by abnormalities in the shape, size, and/or structure of the bones and cartilage.

There are many different types of osteochondrodysplasias, each with its own specific symptoms and patterns of inheritance. Some common examples include achondroplasia, thanatophoric dysplasia, and spondyloepiphyseal dysplasia. These conditions can vary in severity, and some may be associated with other health problems, such as respiratory difficulties or neurological issues.

Treatment for osteochondrodysplasias typically focuses on managing the symptoms and addressing any related health concerns. This may involve physical therapy, bracing or surgery to correct skeletal abnormalities, and treatment for any associated medical conditions. In some cases, genetic counseling may also be recommended for individuals with osteochondrodysplasias and their families.

Acetyl-CoA C-acetyltransferase (also known as acetoacetyl-CoA thiolase or just thiolase) is an enzyme involved in the metabolism of fatty acids and ketone bodies. Specifically, it catalyzes the reaction that converts two molecules of acetyl-CoA into acetoacetyl-CoA, which is a key step in the breakdown of fatty acids through beta-oxidation.

The enzyme works by bringing together two acetyl-CoA molecules and removing a coenzyme A (CoA) group from one of them, forming a carbon-carbon bond between the two molecules to create acetoacetyl-CoA. This reaction is reversible, meaning that the enzyme can also catalyze the breakdown of acetoacetyl-CoA into two molecules of acetyl-CoA.

There are several different isoforms of Acetyl-CoA C-acetyltransferase found in various tissues throughout the body, with differing roles and regulation. For example, one isoform is highly expressed in the liver and plays a key role in ketone body metabolism, while another isoform is found in mitochondria and is involved in fatty acid synthesis.

Arylsulfatases are a group of enzymes that play a role in the breakdown and recycling of complex molecules in the body. Specifically, they catalyze the hydrolysis of sulfate ester bonds in certain types of large sugar molecules called glycosaminoglycans (GAGs).

There are several different types of arylsulfatases, each of which targets a specific type of sulfate ester bond. For example, arylsulfatase A is responsible for breaking down sulfate esters in a GAG called cerebroside sulfate, while arylsulfatase B targets a different GAG called dermatan sulfate.

Deficiencies in certain arylsulfatases can lead to genetic disorders. For example, a deficiency in arylsulfatase A can cause metachromatic leukodystrophy, a progressive neurological disorder that affects the nervous system and causes a range of symptoms including muscle weakness, developmental delays, and cognitive decline. Similarly, a deficiency in arylsulfatase B can lead to Maroteaux-Lamy syndrome, a rare genetic disorder that affects the skeleton, eyes, ears, heart, and other organs.

Microbodies are small, membrane-bound organelles found in the cells of eukaryotic organisms. They typically measure between 0.2 to 0.5 micrometers in diameter and play a crucial role in various metabolic processes, particularly in the detoxification of harmful substances and the synthesis of lipids.

There are several types of microbodies, including:

1. Peroxisomes: These are the most common type of microbody. They contain enzymes that help break down fatty acids and amino acids, producing hydrogen peroxide as a byproduct. Another set of enzymes within peroxisomes then converts the harmful hydrogen peroxide into water and oxygen, thus detoxifying the cell.
2. Glyoxysomes: These microbodies are primarily found in plants and some fungi. They contain enzymes involved in the glyoxylate cycle, a metabolic pathway that helps convert stored fats into carbohydrates during germination.
3. Microbody-like particles (MLPs): These are smaller organelles found in certain protists and algae. Their functions are not well understood but are believed to be involved in lipid metabolism.

It is important to note that microbodies do not have a uniform structure or function across all eukaryotic cells, and their specific roles can vary depending on the organism and cell type.

Acyltransferases are a group of enzymes that catalyze the transfer of an acyl group (a functional group consisting of a carbon atom double-bonded to an oxygen atom and single-bonded to a hydrogen atom) from one molecule to another. This transfer involves the formation of an ester bond between the acyl group donor and the acyl group acceptor.

Acyltransferases play important roles in various biological processes, including the biosynthesis of lipids, fatty acids, and other metabolites. They are also involved in the detoxification of xenobiotics (foreign substances) by catalyzing the addition of an acyl group to these compounds, making them more water-soluble and easier to excrete from the body.

Examples of acyltransferases include serine palmitoyltransferase, which is involved in the biosynthesis of sphingolipids, and cholesteryl ester transfer protein (CETP), which facilitates the transfer of cholesteryl esters between lipoproteins.

Acyltransferases are classified based on the type of acyl group they transfer and the nature of the acyl group donor and acceptor molecules. They can be further categorized into subclasses based on their sequence similarities, three-dimensional structures, and evolutionary relationships.

Peroxisomes are membrane-bound subcellular organelles found in the cytoplasm of eukaryotic cells. They play a crucial role in various cellular processes, including the breakdown of fatty acids and the detoxification of harmful substances such as hydrogen peroxide (H2O2). Peroxisomes contain numerous enzymes, including catalase, which converts H2O2 into water and oxygen, thus preventing oxidative damage to cellular components. They also participate in the biosynthesis of ether phospholipids, a type of lipid essential for the structure and function of cell membranes. Additionally, peroxisomes are involved in the metabolism of reactive oxygen species (ROS) and contribute to the regulation of intracellular redox homeostasis. Dysfunction or impairment of peroxisome function has been linked to several diseases, including neurological disorders, developmental abnormalities, and metabolic conditions.

Multiple hereditary exostoses (MHE) is a genetic condition characterized by the growth of multiple benign tumors known as osteochondromas. These tumors typically develop at the ends of long bones near the growth plates and can cause various skeletal deformities, limitations in mobility, and other health issues.

MHE is usually inherited in an autosomal dominant pattern, meaning that a child has a 50% chance of inheriting the condition if one parent has it. However, some cases may result from spontaneous mutations. The condition typically becomes apparent during childhood or adolescence and can affect both sexes equally.

The primary diagnostic feature of MHE is the presence of multiple osteochondromas, which are made up of bone and cartilage. These growths can cause a range of symptoms, including pain, swelling, decreased mobility, and an increased risk of fractures. In some cases, they may also lead to complications such as nerve compression or vascular damage.

Treatment for MHE typically involves surgical removal of the osteochondromas, particularly if they are causing significant symptoms or complications. Regular monitoring is also important to detect any new growths and assess their potential impact on health. In addition, physical therapy and other supportive measures may be recommended to help manage symptoms and maintain mobility.

Dwarfism is a medical condition that is characterized by short stature, typically with an adult height of 4 feet 10 inches (147 centimeters) or less. It is caused by a variety of genetic and medical conditions that affect bone growth, including skeletal dysplasias, hormonal deficiencies, and chromosomal abnormalities.

Skeletal dysplasias are the most common cause of dwarfism and are characterized by abnormalities in the development and growth of bones and cartilage. Achondroplasia is the most common form of skeletal dysplasia, accounting for about 70% of all cases of dwarfism. It is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene and results in short limbs, a large head, and a prominent forehead.

Hormonal deficiencies, such as growth hormone deficiency or hypothyroidism, can also cause dwarfism if they are not diagnosed and treated early. Chromosomal abnormalities, such as Turner syndrome (monosomy X) or Down syndrome (trisomy 21), can also result in short stature and other features of dwarfism.

It is important to note that people with dwarfism are not "dwarves" - the term "dwarf" is a medical and sociological term used to describe individuals with this condition, while "dwarves" is a term often used in fantasy literature and media to refer to mythical beings. The use of the term "dwarf" can be considered disrespectful or offensive to some people with dwarfism, so it is important to use respectful language when referring to individuals with this condition.

Fibroblasts are specialized cells that play a critical role in the body's immune response and wound healing process. They are responsible for producing and maintaining the extracellular matrix (ECM), which is the non-cellular component present within all tissues and organs, providing structural support and biochemical signals for surrounding cells.

Fibroblasts produce various ECM proteins such as collagens, elastin, fibronectin, and laminins, forming a complex network of fibers that give tissues their strength and flexibility. They also help in the regulation of tissue homeostasis by controlling the turnover of ECM components through the process of remodeling.

In response to injury or infection, fibroblasts become activated and start to proliferate rapidly, migrating towards the site of damage. Here, they participate in the inflammatory response, releasing cytokines and chemokines that attract immune cells to the area. Additionally, they deposit new ECM components to help repair the damaged tissue and restore its functionality.

Dysregulation of fibroblast activity has been implicated in several pathological conditions, including fibrosis (excessive scarring), cancer (where they can contribute to tumor growth and progression), and autoimmune diseases (such as rheumatoid arthritis).

Developmental bone diseases are a group of medical conditions that affect the growth and development of bones. These diseases are present at birth or develop during childhood and adolescence, when bones are growing rapidly. They can result from genetic mutations, hormonal imbalances, or environmental factors such as poor nutrition.

Some examples of developmental bone diseases include:

1. Osteogenesis imperfecta (OI): Also known as brittle bone disease, OI is a genetic disorder that affects the body's production of collagen, a protein necessary for healthy bones. People with OI have fragile bones that break easily and may also experience other symptoms such as blue sclerae (whites of the eyes), hearing loss, and joint laxity.
2. Achondroplasia: This is the most common form of dwarfism, caused by a genetic mutation that affects bone growth. People with achondroplasia have short limbs and a large head relative to their body size.
3. Rickets: A condition caused by vitamin D deficiency or an inability to absorb or use vitamin D properly. This leads to weak, soft bones that can bow or bend easily, particularly in children.
4. Fibrous dysplasia: A rare bone disorder where normal bone is replaced with fibrous tissue, leading to weakened bones and deformities.
5. Scoliosis: An abnormal curvature of the spine that can develop during childhood or adolescence. While not strictly a developmental bone disease, scoliosis can be caused by various underlying conditions such as cerebral palsy, muscular dystrophy, or spina bifida.

Treatment for developmental bone diseases varies depending on the specific condition and its severity. Treatment may include medication, physical therapy, bracing, or surgery to correct deformities and improve function. Regular follow-up with a healthcare provider is essential to monitor growth, manage symptoms, and prevent complications.

Cockroaches are not a medical condition or disease. They are a type of insect that can be found in many parts of the world. Some species of cockroaches are known to carry diseases and allergens, which can cause health problems for some people. Cockroach allergens can trigger asthma symptoms, especially in children. Additionally, cockroaches can contaminate food and surfaces with bacteria and other germs, which can lead to illnesses such as salmonellosis and gastroenteritis.

If you have a problem with cockroaches in your home or workplace, it is important to take steps to eliminate them to reduce the risk of health problems. This may include cleaning up food and water sources, sealing entry points, and using pesticides or hiring a professional pest control service.

"rhizomelic chondrodysplasia punctata". Genetics Home Reference. Retrieved 2017-01-16. "Rhizomelic chondrodysplasia punctata". ... Rhizomelic Chondrodysplasia Punctata, Type 2; RCDP2 - 222765 Online Mendelian Inheritance in Man (OMIM): Rhizomelic ... The mechanism of rhizomelic chondrodysplasia punctata in the case of type 1 of this condition involves a defect in PEX7, whose ... Rhizomelic chondrodysplasia punctata is a rare developmental brain disorder characterized by abnormally short arms and legs ( ...
eds.). "Rhizomelic Chondrodysplasia Punctata Type 1". GeneReviews® [Internet]. University of Washington. PMID 20301447. NBK1270 ... which lead to the development of rhizomelic chondrodysplasia punctata (RCDP) type 2 or 3, respectively. In such cases, both ...
FOXO1A Rhizomelic chondrodysplasia punctata type 1; 215100; PEX7 Rhizomelic chondrodysplasia punctata type 3; 600121; AGPS ... rhizomelic, type 2; 222765; GNPAT Chondrodysplasia punctata, X-linked dominant; 302960; EBP Chondrodysplasia punctata, X-linked ... RP9 Retinitis punctata albescens; 136880; PRPH2 Retinitis punctata albescens; 136880; RLBP1 Retinopathy of prematurity; 133780 ... recessive; 302950; ARSE Chondrodysplasia, Blomstrand type; 215045; PTHR1 Chondrodysplasia, Grebe type; 200700; GDF5 ...
Amelia (birth defect) Rhizomelic chondrodysplasia punctata "Online Medical Dictionary". Archived from the original on 2007-04- ... In turn, short-limb short stature is classified into a) Rhizomelic, b) mesomelic and c) acromelic short stature. Rhizomelic ... According to Stedman's medical dictionary "rhizomelic" means "relating to hip or shoulder joints", while "micromelic" means " ... Typical examples of Rhizomelic short stature are achondroplasia and pseudoachondroplasia. ...
... is an enzyme associated with Rhizomelic chondrodysplasia punctata type 2. GNPAT is located ...
... and rhizomelic chondrodysplasia punctata type 1 (RCDP1). PBD-ZSD represents a continuum of disorders including infantile Refsum ... "Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata". Nature Genetics ...
... is a receptor associated with Refsum's disease and rhizomelic chondrodysplasia punctata type 1. Peroxin GeneReviews/ ... NCBI/NIH/UW entry on Refsum Disease GeneReviews/NIH/NCBI/UW entry on Rhizomelic Chondrodysplasia Punctata Type 1 PEX7+protein,+ ...
These mutations in the PEX7 gene generally lead to rhizomelic chondrodysplasia punctata type 1, which impairs development of ...
Relapsing linear acantholytic dermatosis Restrictive dermopathy Rhizomelic chondrodysplasia punctata (autosomal recessive ... porokeratosis punctata palmaris et plantaris, punctate keratoderma, punctate porokeratosis of the palms and soles) Tyrosinemia ... hyperkeratosis punctata, keratodermia punctata, keratosis punctata, keratotic pits of the palmar creases, lenticular atrophia ... chondrodysplasia punctata type 1, chondrodystrophia calcificans punctata, peroxisomal biogenesis disorder complementation group ...
... chondrodysplasia punctata MeSH C05.116.099.708.195.200 - chondrodysplasia punctata, rhizomelic MeSH C05.116.099.708.207 - ...
... is an enzyme associated with Type 3 Rhizomelic chondrodysplasia punctata. This enzyme catalyses the following chemical reaction ...
549 Rhizomelic chondrodysplasia punctata 215100, 222765, 600121 X-linked recessive chondrodysplasia punctata 302950 Conradi- ... chondrodysplasia punctata 2, x-linked dominant) 302960 Autosomal dominant chondrodysplasia punctata 118650 List of cutaneous ... Chondrodysplasia punctata is a clinically and genetically diverse group of rare diseases, first described by Erich Conradi ( ...
... chondrodysplasia punctata, rhizomelic MeSH C18.452.648.556.750.760 - Refsum disease MeSH C18.452.648.556.750.970 - Zellweger ...
... chondrodysplasia punctata, rhizomelic MeSH C16.320.565.556.750.760 - Refsum disease MeSH C16.320.565.556.750.970 - Zellweger ...
"rhizomelic chondrodysplasia punctata". Genetics Home Reference. Retrieved 2017-01-16. "Rhizomelic chondrodysplasia punctata". ... Rhizomelic Chondrodysplasia Punctata, Type 2; RCDP2 - 222765 Online Mendelian Inheritance in Man (OMIM): Rhizomelic ... The mechanism of rhizomelic chondrodysplasia punctata in the case of type 1 of this condition involves a defect in PEX7, whose ... Rhizomelic chondrodysplasia punctata is a rare developmental brain disorder characterized by abnormally short arms and legs ( ...
Rhizomelic chondrodysplasia punctata. At least three mutations in the AGPS gene have been found to cause rhizomelic ... chondrodysplasia punctata type 3 (RCDP3). These mutations change single protein building blocks (amino acids) in alkylglycerone ...
Rhizomelic chondrodysplasia punctata. At least five mutations in the GNPAT gene have been found to cause rhizomelic ... cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet. ... chondrodysplasia punctata type 2 (RCDP2). These mutations prevent cells from making any functional DHAPAT enzyme. A shortage of ...
Rhizomelic Chondrodysplasia Punctata Type 1 Salla Disease Sickle Cell Anemia Sjögren-Larsson Syndrome Tay-Sachs Disease ... Rhizomelic Chondrodysplasia Punctata Type 1 and our test RCDP1 is a rare genetic disorder. It is characterized by bone ...
Peroxisomal leukoencephalopathies include diseases belonging to the Zellweger spectrum and the rhizomelic chondrodysplasia ... punctata spectrum, as well as some single enzyme defects of peroxisomal β-oxidation. The authors present information on the ... MRI characteristics in the severe phenotype of rhizomelic chondrodysplasia punctata include supratentorial white matter ... leukoencephalopathies include diseases belonging to the Zellweger spectrum and the rhizomelic chondrodysplasia punctata ...
Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. J Ultrasound Med. 1999 Oct. 18(10):715-8. [QxMD ... chondrodysplasia punctate (rhizomelic type); Kniest dysplasia; mesomelic and acromesomelic dysplasia; hypochondroplasia; ... Image shows rhizomelic shortening of the humerus with posterior bowing and an incomplete glenoid fossa. View Media Gallery ... Image shows rhizomelic shortening of the bilateral femurs with metaphyseal flaring. The bones are wide because of unaffected ...
Cranial MR imaging in rhizomelic chondrodysplasia punctata. D W Williams, A D Elster and T D Cox ... Cranial MR imaging in rhizomelic chondrodysplasia punctata. D W Williams, A D Elster and T D Cox ... Cranial MR imaging in rhizomelic chondrodysplasia punctata. D W Williams, A D Elster and T D Cox ...
rhizomelic chondrodysplasia punctata + Rhizomelic Syndrome RHYNS Syndrome Richards-Rundle Syndrome Richieri Costa Da Silva ... chondrodysplasia punctata + chondrodysplasia with joint dislocations gPAPP type chondrodysplasia-pseudohermaphroditism syndrome ...
OMIM:602744: Chondrodysplasia punctata, rhizomelic, type 2. OMIM:222765: *Metabolism (metabolic pathways involving proteins ...
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2. B-Lymphocyte. White. 24 YR. Female. No. 1989. ... RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2. B-Lymphocyte. White. 27 YR. Male. No. 1989. ... RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2. B-Lymphocyte. White. 18 MO. Female. Yes. 1989. ... RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, TYPE 2; RCDP2. Fibroblast. White. 27 MO. Female. Yes. 1989. ...
Rhizomelic chondrodysplasia punctata Symptoms of rhizomelic chondrodysplasia punctata begin in infancy and include a sunken ... Doctors diagnose rhizomelic chondrodysplasia punctata by taking x-rays and testing the blood. ... There is no effective treatment for rhizomelic chondrodysplasia punctata. However, infants who have high blood levels of ... Children may also have short limbs, a specific bone abnormality called chondrodysplasia punctata (which affects the growth of ...
OMIM:601757: Rhizomelic chondrodysplasia punctata, type 1. OMIM:215100: Platelet-activating factor acetylhydrolase IB subunit ...
OMIM:601757: Rhizomelic chondrodysplasia punctata, type 1. OMIM:215100: Platelet-activating factor acetylhydrolase IB subunit ...
... rhizomelic chondrodysplasia punctata and acyl-CoA oxidase deficiency) : novel data Dirk De Craemer (UGent) , MJ Zweens, S ...
Rhizomelic chondrodysplasia punctata type 1 (RCDP1) is caused by mutations in the PEX7 gene. The following SNP related to RCDP1 ... Rhizomelic chondrodysplasia punctata type 2 (RCDP2) is associated with the following SNPs: *rs28939697 ... Conradi-Hunermann syndrome, also known as X-linked dominant chondrodysplasia punctata, is caused by defects in the EPB gene. ... rs1065757 in the arylsulfatase B (ARSB) gene on chromosome 5 may be associated with chondrodysplasia punctata ...
Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. J Ultrasound Med. 1999 Oct. 18(10):715-8. [QxMD ... chondrodysplasia punctate (rhizomelic type); Kniest dysplasia; mesomelic and acromesomelic dysplasia; hypochondroplasia; ... Image shows rhizomelic shortening of the humerus with posterior bowing and an incomplete glenoid fossa. View Media Gallery ... Image shows rhizomelic shortening of the bilateral femurs with metaphyseal flaring. The bones are wide because of unaffected ...
Rhizomelic Chondrodysplasia Punctata. Spina bifida occulta, Scoliosis. ORPHA:177. Acrofacial Dysostosis, Palagonia Type. ...
... rhizomelic chondrodysplasia punctate, chondrodysplasia punctate, mulibrey nanism, chondrodysplasia, osteoporosis, ...
Genetic relation between the Zellweger syndrome, infantile Refsums disease, and rhizomelic chondrodysplasia punctata. Wanders ... Genetic relation between the Zellweger syndrome, infantile Refsums disease, and rhizomelic chondrodysplasia punctata. Wanders ... Genetic relation between the Zellweger syndrome, infantile Refsums disease, and rhizomelic chondrodysplasia punctata. N Engl J ... Genetic relation between the Zellweger syndrome, infantile Refsums disease, and rhizomelic chondrodysplasia punctata. N Engl J ...
Rhizomelic chondrodysplasia punctata From NCATS Genetic and Rare Diseases Information Center. * Rhizomelic chondrodysplasia ... and Neurobehavioral Markers to Genotype Severity-Implications for the Disease Spectrum of Rhizomelic Chondrodysplasia Punctata ...
Rhizomelic Chondrodysplasia Punctata Roberts Syndrome Salivary Tumors Sandhoff Disease Schindler Disease - Type 1 ...
Rhizomelic chondrodysplasia punctata has been reported in infants born to mothers who had SLE antibodies, none of them had ... Rhizomelic chondrodysplasia punctata may be an isolated presentation or occur in association with NLS rash and CNS ... Similar to other NLS manifestation rhizomelic chondrodysplasia punctata occurs as a result of IgG-apoptotic cell complexes ... Shanske AL, Bernstein L, Herzog R (2007) Chondrodysplasia punctata and maternal autoimmune disease: a new case and review of ...
chondrodysplasia punctata DOID:2581 * non-syndromic intellectual disability DOID:0050889 * Vici syndrome ...
rhizomelic chondrodysplasia punctata RCF. right cubital fossa RCL. radial collateral ligament RCM. restrictive cardiomyopathy; ...
Rhizomelic chondrodysplasia punctata See the forum. Forum Rheumatic fever See the forum. ...
Rhizomelic Chondrodysplasia Punctata 6% * Ciliopathy 6% * Diagnostics 6% * Roberts Syndrome 6% * Edema 6% ...
... is characterized by chondrodysplasia punctata (stippled epiphyses), brachytelephalangy (shortening of the distal phalanges), ... can cause CDP with rhizomelic limb shortening. ... X-linked chondrodysplasia punctata 1 (CDPX1) is inherited in an ... Review Chondrodysplasia Punctata 2, X-Linked.[GeneReviews(®). 1993]. Review Chondrodysplasia Punctata 2, X-Linked.. Kumble S, ... CDP = chondrodysplasia punctata; CDPX1 = chondrodysplasia punctata 1, X-linked; MOI = mode of inheritance ...
  • Rhizomelic chondrodysplasia punctata (RCDP) is a type of peroxisomal disorder which impairs the normal development of many parts of the body. (nih.gov)
  • Cassidy McCrone suffered a rare form of dwarfism, rhizomelic chondrodysplasia punctata (RCDP). (dailyrecord.co.uk)
  • The PBD group is comprised of four disorders: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). (ucsc.edu)
  • Although the physiological role of plasmalogens is unclear, defects in their biosynthesis, which occur as a result of peroxisomal disorders, are associated with severe developmental conditions, including rhizomelic chondrodysplasia punctata (RCDP) and Zellweger syndrome . (britannica.com)
  • In rhizomelic chondrodysplasia punctata (RCDP), characterised by proximal limb shortening and mental retardation, peroxisomes are present but of abnormal structure and there are defects of import of some proteins into the organelles. (sas-centre.org)
  • Watch popular content from the following creators: D A U G H F A M(@baidaugh), SAXOLZ(@saxolz1), baby calm down song wrong hand quzzel video#shortnagin #yt shorts #tranding #shorts Elliott was born May 30 with a rare genetic disorder called rhizomelic chondrodysplasia punctata, or RCDP. (ipcphiladelphiadubai.com)
  • We are proud to be a 501 (c) (3) Organization, with our primary objective to raise awareness of RCDP, (Rhizomelic Chondrodysplasia Punctata). (rhizokids.com)
  • An autosomal recessive form of CHONDRODYSPLASIA PUNCTATA characterized by defective plasmalogen biosynthesis and impaired peroxisomes. (jefferson.edu)
  • Chondrodysplasia punctata has variable degrees of severity and outcomes, and variable genetic inheritance including X-linked recessive, X-linked dominant and autosomal recessive. (thefetus.net)
  • Rhizomelic form is autosomal recessive and characterized by rhizomelic shortening of the long bones (humeri and femora) and punctate calcifications of the cartilaginous portions of skeleton, particularly the proximal humeri and femora. (thefetus.net)
  • Researchers have described three types of rhizomelic chondrodysplasia punctata: type 1 (RCDP1), type 2 (RCDP2), and type 3 (RCDP3). (medlineplus.gov)
  • Mutations in this gene have been associated with Refsum disease (RD) and deficient protein activity has been associated with Zellweger syndrome and rhizomelic chondrodysplasia punctata. (abnova.com)
  • It shares many features with other PBDs including those formerly called Zellweger syndrome ( 214100 ), rhizomelic chondrodysplasia punctata ( 215100 ), and neonatal adrenoleukodystrophy ( 601539 ). (arizona.edu)
  • Rhizomelic chondrodysplasia punctata type 1 (RCDP1), a peroxisome biogenesis disorder (PBD) has a classic (severe) form and a nonclassic (mild) form. (nih.gov)
  • Classic (severe) RCDP1 is characterized by proximal shortening of the humerus (rhizomelia) and to a lesser degree the femur, punctate calcifications in cartilage with epiphyseal and metaphyseal abnormalities (chondrodysplasia punctata, or CDP), coronal clefts of the vertebral bodies, and cataracts that are usually present at birth or appear in the first few months of life. (nih.gov)
  • Nonclassic (mild) RCDP1 is characterized by congenital or childhood cataracts, CDP or infrequently, chondrodysplasia manifesting only as mild epiphyseal changes, variable rhizomelia, and milder intellectual disability and growth restriction than classic RCDP1. (nih.gov)
  • Rhizomelic chondrodysplasia punctata type 3 (RCDP3) is a rare genetic disorder that affects bone growth and development. (dnalabsindia.com)
  • Rhizomelic chondrodysplasia punctata is a rare developmental brain disorder characterized by abnormally short arms and legs (rhizomelia), seizures, recurrent respiratory tract infections and congenital cataracts. (wikipedia.org)
  • Congenital heart defects common in rhizomelic chondrodysplasia punctata. (jefferson.edu)
  • The mechanism of rhizomelic chondrodysplasia punctata in the case of type 1 of this condition involves a defect in PEX7, whose product is involved in peroxisome assembly. (wikipedia.org)
  • Clinical History of Patient who is going for AGPS Gene Rhizomelic chondrodysplasia punctata type 3 NGS Genetic DNA Test. (dnalabsindia.com)
  • The cost of AGPS gene rhizomelic chondrodysplasia punctata type 3 NGS genetic DNA testing in India is approximately INR 20,000. (dnalabsindia.com)
  • Rhizomelic chondrodysplasia punctata type 3 is a rare genetic disorder that can have significant physical and cognitive effects. (dnalabsindia.com)
  • At DNA Labs India, we offer comprehensive genetic testing services, including AGPS gene rhizomelic chondrodysplasia punctata type 3 NGS genetic DNA testing, at an affordable cost. (dnalabsindia.com)
  • Diseases associated with PEX5L include Rhizomelic Chondrodysplasia Punctata, Type 5 and Rhizomelic Chondrodysplasia Punctata, Type 2. (antibodiesinc.com)
  • Non-rhizomelic types are characterized by asymmetric, dysplastic skeletal changes, punctate calcifications of the epiphyses, variably asymmetric limb lengths or normal limb lengths, nasal hypoplasia, variable upper airway compromise, skin changes, cataracts, and a generally favorable prognosis. (thefetus.net)
  • cataract, symmetric rhizomelic shortening and epiphyseal calcifications). (fetalmedicine.org)
  • The proximal femoral metaphyses sometimes show chondrodysplasia. (arizona.edu)
  • There are 3 pathways that depend on peroxisomal biogenesis factor 7 activities, including:[verification needed] AGPS (catalyzes plasmalogen biosynthesis) PhYH (catalyzes catabolism of phytanic acid) ACAA1 (catalyzes beta-oxidation of VLCFA - straight) The diagnosis of rhizomelic chondrodysplasia punctata can be based on genetic testing as well as radiography results, plus a physical examination of the individual. (wikipedia.org)
  • Rhizomelic chondrodysplasia punctata has the following symptoms: Bilateral shortening of the femur, resulting in short legs Post-natal growth problems (deficiency) Cataracts Intellectual disability Possible seizures Possible infections of respiratory tract This condition is a consequence of mutations in the PEX7 gene, the GNPAT gene (which is located on chromosome 1) or the AGPS gene. (wikipedia.org)
  • Rhizomelic chondrodysplasia punctata results from mutations in one of three genes. (medlineplus.gov)
  • Mutations in this gene are associated with rhizomelic chondrodysplasia punctata. (oftalmic.ru)
  • Note relatively normal-sized trunk, a large head, rhizomelic shortening of the limbs, lumbar lordosis, and trident hands. (medscape.com)
  • Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, genu varum, and trident hand. (nih.gov)
  • Affected individuals also have a specific bone abnormality called chondrodysplasia punctata, which affects the growth of the long bones and can be seen on x-rays. (medlineplus.gov)
  • Chondrodysplasia punctata is a skeletal abnormality characterized by premature foci of calcification within the cartilage, referred to as stippling. (thefetus.net)
  • Image shows rhizomelic shortening of the bilateral femurs with metaphyseal flaring. (medscape.com)
  • Chondrodysplasia Punctata, Rhizomelic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • The genes associated with rhizomelic chondrodysplasia punctata are involved in the formation and function of structures called peroxisomes . (medlineplus.gov)
  • Ultrasound findings can help identify the subtype of chondrodysplasia punctata based on the location of the stippling and the associated malformations. (thefetus.net)
  • Rhizomelic chondrodysplasia punctata can be subclassified into types 1, 2, and 3 according to the affected gene (PEX7, DHAPAT and ADAPS) and is generally lethal. (thefetus.net)
  • When Do Symptoms of Rhizomelic chondrodysplasia punctata Begin? (nih.gov)
  • Researchers are working to determine how problems with plasmalogen synthesis lead to the specific signs and symptoms of rhizomelic chondrodysplasia punctata. (medlineplus.gov)
  • Rhizomelic chondrodysplasia punctata is associated with significantly delayed development and severe intellectual disability. (medlineplus.gov)
  • Because of their severe health problems, most people with rhizomelic chondrodysplasia punctata survive only into childhood. (medlineplus.gov)
  • The term achondrogenesis has been used to characterize the most severe forms of chondrodysplasia in humans, invariably lethal before or shortly after birth. (nih.gov)
  • Rhizomelic chondrodysplasia punctata affects fewer than 1 in 100,000 people worldwide. (medlineplus.gov)
  • Image shows rhizomelic shortening of the humerus with posterior bowing and an incomplete glenoid fossa. (medscape.com)
  • Warfarin inhibits ARSE activity, so there is a pathophysiological link between fetal warfarin syndrome and chondrodysplasia punctata. (thefetus.net)
  • The metabolic defects associated with the impaired peroxisomes are present only in the rhizomelic form of chondrodysplasia punctata. (jefferson.edu)
  • For example in the dominant form, fine punctata are usually confined to the spine. (thefetus.net)
  • Infant with rhizomelic form of chondrodysplasia punctata (left). (medscape.com)
  • Rhizomelic chondrodysplasia punctata is a uncommon, usually deadly illness that shares many scientific dysmorphologic options with the uncommon usually non-lethal chondrodysplasia punctata as a consequence of maternal autoimmune illness. (molvisindex.org)
  • Growth charts for individuals with rhizomelic chondrodysplasia punctata. (jefferson.edu)
  • Rhizomelic chondrodysplasia punctata is characterized by shortening of the bones in the upper arms and thighs (rhizomelia). (medlineplus.gov)
  • Los defectos metabólicos asociados con la alteración de los peroxisomas sólo están presentes en la forma rizomélica de la condrodisplasia punctata (Scriver et al, Metabolic Basis of Inherited Disease, 6th ed, p 1497). (bvsalud.org)
  • This graph shows the total number of publications written about "Chondrodysplasia Punctata, Rhizomelic" by people in this website by year, and whether "Chondrodysplasia Punctata, Rhizomelic" was a major or minor topic of these publications. (jefferson.edu)
  • People with rhizomelic chondrodysplasia punctata often develop joint deformities (contractures) that make the joints stiff and painful. (medlineplus.gov)
  • Scholia has a topic profile for Rhizomelic chondrodysplasia punctata. (wikipedia.org)